

RGT - 7028  
Therapeutic DNA Vaccination

Serial No. 09/863,606

**Amendments to the Claims**

Claims 1-27 (Cancelled).

28. (new) A method of treating retroviral infection, comprising

i) administering, to a host that is infected with a retrovirus, an antiretroviral therapy, until retroviral replication is suppressed, and then ii) administering a gene delivery complex comprising

a) DNA comprising a nucleic acid sequence encoding at least one immunogenic retroviral protein operably linked with a promoter and b) mannosylated polyethylenimine.

29. (new) The method of Claim 28, wherein the antiretroviral therapy comprises one or more reverse transcriptase inhibitors selected from the group consisting of ddI, d4T, 3TC, AZT, FTC, delavirdine, abacavir, adefovir, nevirapine, efavirenz, lubocavir, PMPA, and PMEA.

30. (new) The method of Claim 28, wherein the antiretroviral therapy comprises one or more protease inhibitors selected from the group consisting of indinavir, saquinavir, ritonavir, nelfinavir, and BMS 23632.

31 (new) The method of Claim 28, wherein the antiretroviral therapy comprises one or more reverse transcriptase inhibitors selected from the group consisting of ddI, d4T, 3TC, AZT, FTC, delavirdine, abacavir, adefovir, nevirapine, efavirenz, lubocavir PMPA, and PMEA; and one or more protease inhibitors selected from the group consisting of indinavir, saquinavir, ritonavir, nelfinavir, and BMS 23632.

32. (new) The method of any one of Claim 28, 29, 30 or 31 wherein the antiretroviral therapy further comprises hydroxyurea.